David P Bonita
CIK 1572451 · last filed 2026-06-18
David P Bonita is a corporate insider who has filed 75 SEC Form 4 insider transactions across 12 companies since 2013. The most recent filing, for IMA, was dated Jun 18, 2026. Across all open-market trades the lifetime net is +$26.5M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $38.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$38.78M
12
75
$26.49M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMA | Director | 753,441 | $5.64 | $4.25M | $2.50M | 3 | 2026-06-18 |
| PRLD | Director | 1,126,126 | $4.68 | $5.27M | $41.00M | 10 | 2026-06-10 |
| Repare Therapeutics Inc. (RPTX) Delisted | Director | 3,177,041 | $2.65 | $8.42M | $11.29M | 11 | 2024-06-20 |
| Third Harmonic Bio, Inc. (THRD) Delisted | Director | 5,779,071 | $5.38 | $31.09M | $5.10M | 5 | 2024-06-10 |
| ImageneBio, Inc. (IKNA) Delisted | Director | 13,107 | $17.16 | $224.9K | $12.42M | 9 | 2024-06-10 |
| Acutus Medical, Inc. (AFIB) Delisted | Director | 1,698,183 | $0.09 | $152.8K | $22.47M | 6 | 2023-06-15 |
| Tricida, Inc. (TCDA) Delisted | Director | 9,274,110 | $0.11 | $1.00M | -$47.11M | 9 | 2022-11-25 |
| IMRA | Director | 1,049,767 | $14.46 | $15.18M | $35.00M | 5 | 2022-06-03 |
| SIBN | Director | 785,368 | $17.93 | $14.08M | $3.00M | 1 | 2018-10-19 |
| ViewRay, Inc. (VRAY) Delisted | Director | 115,613 | $0.03 | $2.9K | $4.35M | 4 | 2018-04-25 |
| Loxo Oncology, Inc. (LOXO) Delisted | Director | 941,000 | — | — | -$69.20M | 9 | 2017-12-12 |
| AMBIT BIOSCIENCES CORP (AMBI) Delisted | Director | 13,947 | $0.54 | $7.5K | $5.66M | 2 | 2013-05-24 |
Recent Filings
75 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-18 | IMA | Grant (A) | — | $0 | EDGAR |
| 2026-06-10 | PRLD | Grant (A) | — | $0 | EDGAR |
| 2026-04-23 | PRLD | Buy (P) | +2,815,315 | $12.50M | EDGAR |
| 2026-04-16 | IMA | Buy (P) | — | $0 | EDGAR |
| 2025-08-14 | — | Other (J) | −5,779,071 | $0 | |
| 2025-07-30 | IMA | Mixed | +83,990 | $2.50M | EDGAR |
| 2025-06-13 | PRLD | Grant (A) | — | $0 | EDGAR |
| 2024-06-20 | Repare Therapeutics Inc. (RPTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-18 | PRLD | Grant (A) | — | $0 | EDGAR |
| 2024-06-10 | Third Harmonic Bio, Inc. (THRD) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.